A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Biohaven Therapeutics Ltd.
Study ID
NCT07262268
Phase
PHASE1
Status
Enrolling By Invitation

Conditions

  • Familial Erythromelalgia

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • BHV-7000 — DRUG
    Participants will take blinded investigational product (IP) orally once daily
  • Placebo — DRUG
    Matching placebo taken orally once daily

Study Details

The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.

Key Dates

Start date
Jan 15, 2026
Status verified
Apr 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
5 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: BHV-7000
  • Placebo Comparator: Placebo

Primary Outcome Measure

Mean of the daily average maximum pain intensity scores collected every 2 hours. [ Time Frame: The last 3 weeks of each 4-week crossover treatment period ]

Locations (1)

FacilityCityStateZIPSite coordinators
Site-001New HavenConnecticut06520-

Find similar trials in New Haven, CT

By research site
Site-001· New Haven, CT